{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:31:28Z","timestamp":1791923488176,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajt.2025.07.2471","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T23:20:30Z","timestamp":1753140030000},"page":"2621-2633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in cytomegalovirus-seronegative recipients of cytomegalovirus-seropositive donor kidneys: Post hoc analysis of a randomized, phase 3 trial of letermovir vs valganciclovir prophylaxis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-5942","authenticated-orcid":false,"given":"Klemens","family":"Budde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1930-8964","authenticated-orcid":false,"given":"Nassim","family":"Kamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6992-6379","authenticated-orcid":false,"given":"Marta","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0601-6615","authenticated-orcid":false,"given":"Catherine B.","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6743-1483","authenticated-orcid":false,"given":"Nicole","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1512-2838","authenticated-orcid":false,"given":"Natalya","family":"Broyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7785-3229","authenticated-orcid":false,"given":"Christopher L.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-7596","authenticated-orcid":false,"given":"Pamela","family":"Moise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6315-5470","authenticated-orcid":false,"given":"Barbara","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajt.2025.07.2471_bib1","article-title":"Viral load kinetics and the clinical consequences of cytomegalovirus in kidney transplantation","volume":"14","author":"Dobrer","year":"2023","journal-title":"Front Immunol"},{"issue":"suppl 2","key":"10.1016\/j.ajt.2025.07.2471_bib2","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/01.tp.0000230460.42558.b0","article-title":"The natural course of cytomegalovirus infection and disease in renal transplant recipients","volume":"82","author":"Hartmann","year":"2006","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ajt.2025.07.2471_bib3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1523-1755.2004.00735.x","article-title":"Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival","volume":"66","author":"Sagedal","year":"2004","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ajt.2025.07.2471_bib4","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1681\/ASN.0000000000000090","article-title":"A randomized trial of valganciclovir prophylaxis versus preemptive therapy in kidney transplant recipients","volume":"34","author":"Reischig","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.ajt.2025.07.2471_bib5","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/tri.14122","article-title":"Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta-analysis","volume":"34","author":"Ruenroengbun","year":"2021","journal-title":"Transpl Int."},{"issue":"5","key":"10.1016\/j.ajt.2025.07.2471_bib6","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.ajt.2025.07.2471_bib7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1600-6143.2007.02133.x","article-title":"Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial","volume":"8","author":"Kliem","year":"2008","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2025.07.2471_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13577","article-title":"The burden of cytomegalovirus infection remains high in high-risk kidney transplant recipients despite six-month valganciclovir prophylaxis","volume":"23","author":"R\u00e4ih\u00e4","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"10.1016\/j.ajt.2025.07.2471_bib9","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/TP.0000000000000570","article-title":"Evaluation of low- versus high-dose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients","volume":"99","author":"Gabardi","year":"2015","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.ajt.2025.07.2471_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/tid.12349","article-title":"Increased risk of breakthrough infection among cytomegalovirus donor-positive\/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis","volume":"17","author":"Stevens","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"10.1016\/j.ajt.2025.07.2471_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1399-3062.2011.00624.x","article-title":"Risk factors for late-onset cytomegalovirus disease in donor seropositive\/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis","volume":"13","author":"Boudreault","year":"2011","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"10.1016\/j.ajt.2025.07.2471_bib12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1086\/528718","article-title":"Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation","volume":"46","author":"Arthurs","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajt.2025.07.2471_bib13","series-title":"US prescribing information. Rahway, NJ, USA: Merck Sharp & Dohme Corp","year":"2024"},{"issue":"1","key":"10.1016\/j.ajt.2025.07.2471_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ajt.2025.07.2471_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"issue":"6","key":"10.1016\/j.ajt.2025.07.2471_bib16","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.ajt.2025.07.2471_bib17","series-title":"US prescribing information","year":"2021"},{"issue":"2","key":"10.1016\/j.ajt.2025.07.2471_bib18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jac\/dkv342","article-title":"Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?","volume":"71","author":"Billat","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ajt.2025.07.2471_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14227","article-title":"Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease","volume":"26","author":"Belga","year":"2024","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"10.1016\/j.ajt.2025.07.2471_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14583","article-title":"Outcomes among CMV-mismatched and highly sensitized kidney transplants recipients who develop neutropenia","volume":"36","author":"Brar","year":"2022","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2025.07.2471_bib21","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.transproceed.2008.02.048","article-title":"Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil","volume":"40","author":"Brum","year":"2008","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.ajt.2025.07.2471_bib22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ndt\/gfl539","article-title":"Unexpected rate of severe leucopenia with the association of mycophenolate mofetil and valganciclovir in kidney transplant recipients","volume":"22","author":"Rerolle","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ajt.2025.07.2471_bib23","series-title":"US prescribing information","year":"2022"},{"issue":"1","key":"10.1016\/j.ajt.2025.07.2471_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13457","article-title":"Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients","volume":"23","author":"Schaenman","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"10.1016\/j.ajt.2025.07.2471_bib25","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ckj\/sfx145","article-title":"High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation","volume":"11","author":"Rissling","year":"2018","journal-title":"Clin Kidney J"},{"issue":"7","key":"10.1016\/j.ajt.2025.07.2471_bib26","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1093\/cid\/ciz1113","article-title":"Burden and timeline of infectious diseases in the first year after solid organ transplantation in the Swiss transplant cohort study","volume":"71","author":"van Delden","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajt.2025.07.2471_bib27","series-title":"US prescribing information","year":"2005"},{"issue":"1","key":"10.1016\/j.ajt.2025.07.2471_bib28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajt.2025.07.2471_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2022.10332","article-title":"Cytomegalovirus management in solid organ transplant recipients: a pre-COVID-19 survey from the Working Group of the European Society for Organ Transplantation","volume":"35","author":"Grossi","year":"2022","journal-title":"Transpl Int"},{"issue":"1","key":"10.1016\/j.ajt.2025.07.2471_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14000","article-title":"Burden of neutropenia and leukopenia among adult kidney transplant recipients: a systematic literature review of observational studies","volume":"25","author":"Raval","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.ajt.2025.07.2471_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14233","article-title":"Five-year single-center analysis of cytomegalovirus viremia in kidney transplant recipients and possible implication for novel prophylactic therapy approaches","volume":"26","author":"Trappe","year":"2024","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"10.1016\/j.ajt.2025.07.2471_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02684-21","article-title":"Detection of ganciclovir-resistant cytomegalovirus in a prospective cohort of kidney transplant recipients receiving subtherapeutic valganciclovir prophylaxis","volume":"10","author":"Wong","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"6","key":"10.1016\/j.ajt.2025.07.2471_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz215","article-title":"Risk factors for failure of primary (val)ganciclovir prophylaxis against cytomegalovirus infection and disease in solid organ transplant recipients","volume":"6","author":"Khurana","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ajt.2025.07.2471_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620958910","article-title":"The art and science of drug titration","volume":"11","author":"Caffrey","year":"2020","journal-title":"Ther Adv Drug Saf"},{"issue":"45","key":"10.1016\/j.ajt.2025.07.2471_bib35","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.15585\/mmwr.mm6645a2","article-title":"CDC Grand Rounds: improving medication adherence for chronic disease management - innovations and opportunities","volume":"66","author":"Neiman","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.ajt.2025.07.2471_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14962","article-title":"Factors impacting the medication \u201cAdherence Landscape\u201d for transplant patients","volume":"37","author":"Bendersky","year":"2023","journal-title":"Clin Transplant"},{"issue":"5","key":"10.1016\/j.ajt.2025.07.2471_bib37","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.transproceed.2007.02.074","article-title":"Medication adherence in chronic disease: issues in posttransplant immunosuppression","volume":"39","author":"Hansen","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ajt.2025.07.2471_bib38","first-page":"115","article-title":"One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects","volume":"4","author":"Airoldi","year":"2010","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"10.1016\/j.ajt.2025.07.2471_bib39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/jorc.12181","article-title":"Medication adherence after renal transplantation-a review of the literature","volume":"42","author":"Rebafka","year":"2016","journal-title":"J Ren Care"},{"issue":"5","key":"10.1016\/j.ajt.2025.07.2471_bib40","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1432-2277.2008.00827.x","article-title":"Medication-taking among adult renal transplant recipients: barriers and strategies","volume":"22","author":"Gordon","year":"2009","journal-title":"Transpl Int"},{"issue":"6","key":"10.1016\/j.ajt.2025.07.2471_bib41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/tid.12133","article-title":"Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation","volume":"15","author":"Posadas Salas","year":"2013","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"10.1016\/j.ajt.2025.07.2471_bib42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1399-3062.2000.020303.x","article-title":"Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis","volume":"2","author":"Rubin","year":"2000","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ajt.2025.07.2471_bib43","first-page":"S62","article-title":"Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?","volume":"57","author":"Goral","year":"1996","journal-title":"Kidney Int Suppl"},{"issue":"suppl B","key":"10.1016\/j.ajt.2025.07.2471_bib44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/jac\/12.suppl_B.153","article-title":"Use of acyclovir for prophylaxis of herpes infections in severely immunocompromised patients","volume":"12","author":"Prentice","year":"1983","journal-title":"J Antimicrob Chemother"},{"issue":"21","key":"10.1016\/j.ajt.2025.07.2471_bib45","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJM198905253202105","article-title":"A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts","volume":"320","author":"Balfour","year":"1989","journal-title":"N Engl J Med"},{"issue":"8967","key":"10.1016\/j.ajt.2025.07.2471_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(95)92110-9","article-title":"Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients","volume":"346","author":"Winston","year":"1995","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ajt.2025.07.2471_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1034\/j.1399-3062.1999.010202.x","article-title":"High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients","volume":"1","author":"Barkholt","year":"1999","journal-title":"Transpl Infect Dis"},{"issue":"8","key":"10.1016\/j.ajt.2025.07.2471_bib48","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V99.8.3050","article-title":"Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants","volume":"99","author":"Ljungman","year":"2002","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ajt.2025.07.2471_bib49","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","article-title":"Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group","volume":"340","author":"Lowance","year":"1999","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ajt.2025.07.2471_bib50","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"issue":"18","key":"10.1016\/j.ajt.2025.07.2471_bib51","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1001\/jama.2023.18025","article-title":"Letermovir vs valganciclovir for cytomegalovirus prophylaxis after kidney transplant-reply","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ajt.2025.07.2471_bib52","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1097\/TP.0000000000005098","article-title":"Comparison of eGFR equations to guide dosing of medications for kidney transplant recipients","volume":"108","author":"Akbari","year":"2024","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.ajt.2025.07.2471_bib53","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1128\/AAC.00375-13","article-title":"Electronic estimations of renal function are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir","volume":"57","author":"Trevillyan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ajt.2025.07.2471_bib54","first-page":"213","article-title":"Discordance between using estimated and measured glomerular filtration rate for drug dosing in kidney transplant recipients","volume":"15","author":"Nabiee","year":"2021","journal-title":"Iran J Kidney Dis"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613525028503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613525028503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:35:30Z","timestamp":1778621730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613525028503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1600613525028503"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2025.07.2471","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in cytomegalovirus-seronegative recipients of cytomegalovirus-seropositive donor kidneys: Post hoc analysis of a randomized, phase 3 trial of letermovir vs valganciclovir prophylaxis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2025.07.2471","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates and The Author(s). Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons.","name":"copyright","label":"Copyright"}]}}